{
    "clinical_study": {
        "@rank": "63592", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. Subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for a total of 4 weeks."
            }, 
            {
                "arm_group_label": "Potassium chloride powder", 
                "arm_group_type": "Active Comparator", 
                "description": "Potassium chloride powder, identical in appearance to potassium citrate powder, will contain 20 meq KCl per sachet. Subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for a total of 4 weeks."
            }, 
            {
                "arm_group_label": "Potassium citrate powder", 
                "arm_group_type": "Active Comparator", 
                "description": "Potassium citrate powder will contain 20 meq KCl per sachet. Subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as citrate) per day for a total of 4 weeks."
            }, 
            {
                "arm_group_label": "Potassium magnesium citrate powder", 
                "arm_group_type": "Experimental", 
                "description": "Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for a total of 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Liquid potassium-magnesium citrate (KMgCit) as a pharmaceutical formulation will lower blood\n      pressure among patients with pre- or Stage I hypertension on their customary diet."
        }, 
        "brief_title": "Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "In this protocol, the investigators want to explore whether KMgCit taken during a customary\n      dietary setting, might serve as a \"surrogate\" for the DASH diet to lower blood pressure.\n      This study has obvious biomedical importance. Lifestyle modifications are often recommended\n      for pre- or Stage I hypertension. The DASH diet is such a modification that has been shown\n      to be effective. However, this diet is costly and difficult to adhere to long-term. If\n      KMgCit were shown to be effective in lowering blood pressure, it would provide a safe and\n      convenient alternative to the DASH diet."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women > 21 years of age\n\n          -  Any Race/Ethnicity\n\n          -  Pre- or Stage I hypertension (BP >= 120/80 and <= 159/99)\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus\n\n          -  Renal impairment (serum creatinine > 1.4 mg/dL)\n\n          -  Any heart diseases such as congestive heart failure or sustained arrhythmia\n\n          -  Chronic NSAID use\n\n          -  Treatment with diuretics\n\n          -  Gastroesophageal reflux disease (GERD) requiring treatment with acid reducing agents\n             or antacid more than once a week\n\n          -  Esophageal-gastric ulcer\n\n          -  Chronic diarrhea\n\n          -  Hyperkalemia (serum > 4.6 mEq/L for patients on ACE inhibitors or ARBs, serum K > 5.0\n             for patient not on ACE inhibitors or ARBs)\n\n          -  Abnormal liver function test (AST or ALT above upper limit of normal range)\n\n          -  Subjects who require any potassium supplement on a regular basis from any reasons\n\n          -  Pregnancy\n\n          -  History of major depression, bipolar disorder, or schizophrenia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682837", 
            "org_study_id": "LiqKMgCit-1208-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Potassium chloride powder", 
                "description": "1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks", 
                "intervention_name": "Potassium chloride powder", 
                "intervention_type": "Drug", 
                "other_name": "KCl"
            }, 
            {
                "arm_group_label": "Potassium citrate powder", 
                "description": "1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks", 
                "intervention_name": "Potassium citrate powder", 
                "intervention_type": "Drug", 
                "other_name": "KCit"
            }, 
            {
                "arm_group_label": "Potassium magnesium citrate powder", 
                "description": "1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks", 
                "intervention_name": "Potassium magnesium citrate powder", 
                "intervention_type": "Drug", 
                "other_name": "KMgCit"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Microcystalline cellulose"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Magnesium citrate", 
                "Potassium Citrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 29, 2012", 
        "location": {
            "contact": {
                "email": "Debbie.Arbique@UTSouthwestern.edu", 
                "last_name": "Debbie Arbique, DNP", 
                "phone": "214-648-2968"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "Hypertension Clinic - UT Southwestern Medical Center at Dallas"
            }, 
            "investigator": {
                "last_name": "Wanpen Vongpatanasin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension", 
        "overall_contact": {
            "email": "debbie.arbique@utsouthwestern.edu", 
            "last_name": "Debbie Arbique, DNP", 
            "phone": "214-648-2968"
        }, 
        "overall_official": {
            "affiliation": "University of Texas Southwestern Medical Center", 
            "last_name": "Wanpen Vongpatanasin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24-hour blood pressure", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Office blood pressure", 
                "safety_issue": "No", 
                "time_frame": "2 and 4 weeks"
            }, 
            {
                "measure": "Serum C-terminal telopeptide (CTX)", 
                "safety_issue": "No", 
                "time_frame": "2 and 4 weeks"
            }, 
            {
                "measure": "24-hour urinary calcium", 
                "safety_issue": "No", 
                "time_frame": "4 weeks of treatment"
            }, 
            {
                "measure": "Carotid to femoral pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Central aortic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Meta Pharm Development, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Meta Pharm Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}